Celularity (NASDAQ:CELU) Trading Down 10.4% – Here’s Why

Celularity, Inc. (NASDAQ:CELU) fell 10.4% on Monday . The company traded as low as $1.1750 and last traded at $1.20. 183,327 shares traded hands during trading, an increase of 161% from the average session volume of 70,298 shares. The stock had previously closed at $1.34.

Analyst Upgrades and Downgrades

CELU has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Celularity in a report on Wednesday, October 8th. Wall Street Zen downgraded Celularity from a “hold” rating to a “sell” rating in a research report on Friday, September 5th. Finally, WBB Securities upgraded Celularity from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Tuesday, September 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Celularity presently has a consensus rating of “Hold” and an average price target of $6.00.

Celularity Trading Down 10.4%

The stock has a market cap of $34.18 million, a P/E ratio of -0.36 and a beta of 0.77. The business has a 50-day simple moving average of $1.73 and a 200 day simple moving average of $2.28.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.62. Celularity had a negative return on equity of 459.57% and a negative net margin of 198.75%.The company had revenue of $5.28 million during the quarter.

Institutional Investors Weigh In On Celularity

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd boosted its position in shares of Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after purchasing an additional 11,057 shares in the last quarter. Perennial Investment Advisors LLC acquired a new position in Celularity in the third quarter valued at approximately $28,000. Acadian Asset Management LLC bought a new position in shares of Celularity during the 1st quarter worth approximately $34,000. Bank of America Corp DE grew its position in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the period. Finally, HB Wealth Management LLC acquired a new stake in shares of Celularity during the 3rd quarter worth approximately $84,000. 19.02% of the stock is owned by institutional investors.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.